Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma

This study has been terminated.
(High patient withdrawal rate)
Sponsor:
Collaborator:
Genentech, Inc.
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance
ClinicalTrials.gov Identifier:
NCT01009203
First received: November 5, 2009
Last updated: July 14, 2015
Last verified: July 2015

November 5, 2009
July 14, 2015
December 2009
September 2012   (final data collection date for primary outcome measure)
Progression Free Survival (PFS) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
The time from treatment initiation to disease progression or death by any cause. Progression is evaluated according to modified Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Target lesions are assessed by computerized tomography (CT) or magnetic resonance imaging (MRI): Progressive Disease (PD), 20% increase in the sum of the longest diameter of target lesions, or unequivocal progression of existing non-target lesion, the appearance of new lesions, death due to disease without prior objective documentation of progression, or global deterioration in health status attributable to disease requiring a change in therapy without objective evidence of progression.
To evaluate the clinical efficacy of the combination of Torisel and Tarceva in patients with advanced, platinum-refractory or -ineligible, squamous cell carcinoma of the head and neck. [ Time Frame: 3 years ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01009203 on ClinicalTrials.gov Archive Site
  • Toxicity Profile [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
    Toxicities (i.e. Adverse Events) are evaluated prior to each treatment and during any clinical visit. Toxicity will be evaluated per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), version 3.0. The number of patients affected by adverse events of grade 3 or higher will be reported.
  • Overall Response Rate (ORR) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    Tumor response is evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) (version 1.0). Target lesions are assessed by computerized tomography (CT) or magnetic resonance imaging (MRI:) Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions. Overall response rate (ORR) is the sum of the percentages of patients achieving complete and partial responses
  • Overall Survival (OS) [ Time Frame: 3 years ] [ Designated as safety issue: No ]
    The time from treatment initiation to death by any cause
To determine the toxicities of the combination of Torisel and Tarceva in patients with advanced, platinum-refractory or -ineligible SCCHN. [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory/Ineligible, Advanced, Squamous Cell Carcinoma
A Phase II Study of Temsirolimus (Torisel®) and Erlotinib (Tarceva®) in Platinum-Refractory or -Ineligible, Advanced, Squamous Cell Carcinoma of the Head and Neck
The primary hypothesis of this study is that the addition of mammalian target of rapamycin (mTOR) blockade to conventional epidermal growth factor receptor (EGFR) blockade will result in synergistic clinical activity in Squamous Cell Carcinoma of the Head and Neck (SCCHN), consistent with preclinical xenograft data. Patients will be treated with the combination of temsirolimus and erlotinib, at the previously established Maximal Tolerated Dose (MTD). The primary signal of efficacy will be progression free survival (PFS), anticipating that PFS will be prolonged compared to historical PFS in SCCHN patients treated with erlotinib or cetuximab monotherapy.
This is a phase II, multicenter, single arm, open-label study. Thirty-seven patients with advanced, platinum-refractory or platinum-ineligible squamous cell carcinoma of the head and neck will be sequentially enrolled to a single treatment arm. Patients will be treated with continuous, 28-day cycles of 150 mg of erlotinib by mouth daily and 15 mg of temsirolimus intervenously weekly. In the absence of grade 3 or higher toxicity in the first cycle, a single, intra-patient dose increase to 20 mg temsirolimus will be permitted.
Interventional
Phase 2
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Squamous Cell Carcinoma
  • Drug: Erlotinib
    Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
    Other Names:
    • Tarceva
    • OSI-774
  • Drug: Temsirolimus
    In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
    Other Names:
    • Torisel
    • CCI-779
Experimental: Temsirolimus and Erlotinib
Erlotinib (Tarceva) at 150 mg by mouth daily + Temsirolimus (Torisel) at 15 mg intravenously weekly. Each cycle is comprised of 28 days
Interventions:
  • Drug: Erlotinib
  • Drug: Temsirolimus
Bauman JE, Arias-Pulido H, Lee SJ, Fekrazad MH, Ozawa H, Fertig E, Howard J, Bishop J, Wang H, Olson GT, Spafford MJ, Jones DV, Chung CH. A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol. 2013 May;49(5):461-7. doi: 10.1016/j.oraloncology.2012.12.016. Epub 2013 Feb 4.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
13
December 2012
September 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Histologically or cytologically confirmed squamous cell carcinoma of the head and neck, from any primary site. Nasopharyngeal carcinoma, World Health Organization (WHO) Grade I, will be included.
  2. Advanced disease, fulfilling one of the criteria defined below:

    • Incurable disease as assessed by surgical or radiation oncology
    • Metastatic (M1) disease
    • Persistent or progressive disease following curative-intent radiation, and not a candidate for surgical salvage due to incurability or morbidity
  3. Platinum-refractory or platinum-ineligible, fulfilling one of the criteria defined below:

    • disease progression during or after 4-6 cycles of platinum-containing therapy in the advanced setting
    • disease progression within 6 months of curative-intent treatment, which included platinum-based chemotherapy
    • ineligible for platinum-containing therapy, in the opinion of the medical oncologist, due to medical comorbidities or unacceptable risk for toxicity
    • patient refuses platinum-containing therapy
  4. Measurable disease based on response evaluation criteria in solid tumors (RECIST)

    - disease in previously irradiated sites is considered measurable if there has been unequivocal progression of the lesion after radiotherapy, or the lesion contains residual carcinoma by biopsy more than 6 weeks after completion of radiotherapy

  5. Easter Cooperative Oncology Group (ECOG) performance status 0-2 at time of informed consent
  6. Adequate hematologic reserve and organ function

    • Absolute neutrophil count > 1200/µl
    • Platelet count > 100,000/µl
    • Renal function: Serum Creatinine ≤ 1.5x upper limit of normal (ULN)
    • Liver function: Total bilirubin ≤ 1.5x ULN, Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5x ULN
  7. Able to provide written, voluntary consent
  8. Patients with reproductive potential must use an effective contraceptive method.
  9. Male or female, age ≥ 18 years
  10. Life expectancy ≥ 12 weeks

Exclusion Criteria:

  1. Nasopharyngeal primary site, if WHO grade II or III
  2. Prior treatment blocking the epidermal growth factor receptor (EGFR), in the advanced disease setting
  3. Prior treatment blocking EGFR in the curative-intent setting, if delivered in the previous 6 months
  4. Prior treatment with a drug blocking the mammalian target of rapamycin (mTOR)
  5. Sensitivity to temsirolimus or erlotinib
  6. Uncontrolled metastatic disease of the central nervous system
  7. Radiotherapy within the 2 weeks before Cycle 1' Day 1
  8. Surgery within the 2 weeks before Cycle 1' Day 1
  9. Pregnant or lactating females
  10. Myocardial infarction or ischemia within the 6 months preceding study treatment
  11. Any co morbid condition that' in the view of the attending physician' renders the patient at high risk from treatment complications
  12. No other concurrent, investigational anti-neoplastic agent will be permitted
  13. History of prior malignancy within the prior five years, with the exception of non-melanoma carcinomas of the skin, and carcinoma in situ of the cervix
Both
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01009203
INST OSI4641s, OSI4641s, NCI-2011-02948
Yes
Not Provided
Not Provided
New Mexico Cancer Care Alliance
New Mexico Cancer Care Alliance
Genentech, Inc.
Principal Investigator: Homan Fekrazad, MD University of New Mexico Cancer Center
New Mexico Cancer Care Alliance
July 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP